Hepatitis: all 3,372 studies

Page 5 of 34. Open to participants first (195), then studies with results posted, then the rest; newest registration first within each.

• Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis CCompletedNCT02640547Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT02640482Phase 3Results posted
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedNCT02640157Phase 3Results posted
• Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infectionCompletedNCT02637999Phase 1/2Results posted
• Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in HungaryCompletedNCT02636608Results posted
• The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)CompletedNCT02636595Phase 3Results posted
• LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant RecipientsCompletedNCT02631772Phase 4Results posted
• Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.CompletedNCT02625909Phase 3Results posted
• The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in FranceCompletedNCT02618928Results posted
• Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)CompletedNCT02615145Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV CoinfectionCompletedNCT02613871Phase 3Results posted
• Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)TerminatedNCT02613403Phase 2Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedNCT02609659Phase 3Results posted
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyCompletedNCT02607800Phase 3Results posted
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral TherapyCompletedNCT02607735Phase 3Results posted
• 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOFTerminatedNCT02605304Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 InfectionCompletedNCT02604017Phase 3Results posted
• Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani PopulationCompletedNCT02601976Phase 4Results posted
• The Patient-Reported Outcomes Project of HCV-TARGETCompletedNCT02601820Results posted
• Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedNCT02601573Phase 2Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based TherapiesTerminatedNCT02600351Phase 3Results posted
• Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCVCompletedNCT02600325Phase 3Results posted
• A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected SubjectsCompletedNCT02597790Results posted
• The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in IrelandCompletedNCT02582671Results posted
• Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)CompletedNCT02582658Results posted
• A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected AdultsCompletedNCT02582632Phase 3Results posted
• Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in CanadaCompletedNCT02581189Results posted
• Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in BelgiumCompletedNCT02581163Results posted
• Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being TreatedCompletedNCT02579382Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and SimeprevirCompletedNCT02569710Phase 2Results posted
• An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis CCompletedNCT02557646Results posted
• A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) PatientsCompletedNCT02556307Results posted
• Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-respondersCompletedNCT02540538Phase 1Results posted
• Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver TransplantCompletedNCT02533934Phase 4Results posted
• ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated CirrhosisCompletedNCT02517528Phase 3Results posted
• ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02517515Phase 3Results posted
• An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in AustriaCompletedNCT02515279Results posted
• Treatment of Chronic Delta Hepatitis With Lonafarnib and RitonavirCompletedNCT02511431Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular CarcinomaTerminatedNCT02504099Phase 3Results posted
• Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)TerminatedNCT02503735Not applicableResults posted
• Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis BCompletedNCT02496897Phase 1Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02493855Phase 2Results posted
• Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney DiseaseCompletedNCT02487199Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedNCT02487030Phase 3Results posted
• A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedNCT02486406Phase 2/3Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionCompletedNCT02480712Phase 3Results posted
• Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6CompletedNCT02480166Phase 4Results posted
• Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus InfectionTerminatedNCT02479880Phase 4Results posted
• Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02476617Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionCompletedNCT02472886Phase 3Results posted
• Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816CompletedNCT02468648Phase 2Results posted
• 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir StudyTerminatedNCT02465203Phase 3Results posted
• Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized TrialCompletedNCT02463331Phase 4Results posted
• Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PROCompletedNCT02461745Phase 4Results posted
• A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)CompletedNCT02461563Phase 1Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-InfectionCompletedNCT02457611Phase 2Results posted
• Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of CirrhosisTerminatedNCT02455167Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedNCT02446717Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT02442284Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in BrazilCompletedNCT02442271Phase 3Results posted
• A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530CompletedNCT02441283Phase 2/3Results posted
• Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryCompletedNCT02422264Phase 4Results posted
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02421211Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 InfectionCompletedNCT02413593Phase 2Results posted
• Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative VolunteersCompletedNCT02404805Not applicableResults posted
• CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeSCompletedNCT02402218Not applicableResults posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected AdultsCompletedNCT02399345Phase 3Results posted
• Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)CompletedNCT02392494Phase 1Results posted
• Add-on Peginterferon Following Nucleos(t)Ide Analogue TreatmentCompletedNCT02364336Phase 2Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)CompletedNCT02358044Phase 3Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation SettingCompletedNCT02350569Phase 2Results posted
• Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02349048Phase 2Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV InfectionCompletedNCT02346721Phase 3Results posted
• Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedNCT02340962Phase 2Results posted
• Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of ColumbiaCompletedNCT02339038Phase 4Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedNCT02332720Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)CompletedNCT02332707Phase 2Results posted
• Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic HepatitisCompletedNCT02331589Phase 4Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 CirrhoticsCompletedNCT02304159Phase 4Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell DiseaseCompletedNCT02301936Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C InfectionTerminatedNCT02292706Results posted
• A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected ParticipantsCompletedNCT02268864Phase 2Results posted
• A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)CompletedNCT02265237Phase 3Results posted
• A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant PhaseCompletedNCT02263079Phase 3Results posted
• An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedNCT02262728Phase 2Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)CompletedNCT02252016Phase 3Results posted
• Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)CompletedNCT02251990Phase 3Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3Results posted
• Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in EgyptCompletedNCT02247401Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedNCT02243293Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 InfectionCompletedNCT02243280Phase 2Results posted
• sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITISCompletedNCT02239562Phase 1Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and CirrhosisCompletedNCT02226549Phase 2Results posted
• Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated CirrhosisCompletedNCT02224456Phase 4Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionCompletedNCT02220998Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and CirrhosisCompletedNCT02219503Phase 3Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02219490Phase 3Results posted

← Hepatitis overview